The estimated Net Worth of Bali Muralidhar is at least $13.2 Million dollars as of 19 May 2022. Mr. Muralidhar owns over 1,472,126 units of Exicure Inc stock worth over $13,096,145 and over the last 5 years he sold XCUR stock worth over $0. In addition, he makes $109,468 as Independent Director at Exicure Inc.
Sign up
Mr. Muralidhar XCUR stock SEC Form 4 insiders trading
Bali has made over 3 trades of the Exicure Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 1,472,126 units of XCUR stock worth $279,704 on 19 May 2022.
The largest trade he's ever made was buying 1,472,126 units of Exicure Inc stock on 19 May 2022 worth over $279,704. On average, Bali trades about 218,102 units every 80 days since 2019. As of 19 May 2022 he still owns at least 8,449,126 units of Exicure Inc stock.
You can see the complete history of Mr. Muralidhar stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Bali Muralidhar biography
Bali Muralidhar M.D., Ph.D. serves as Independent Director of the Company. He has served as a member of our Board of Directors since August 2019. Dr. Muralidhar has served as partner at Abingworth LLP, an international investment group dedicated to life sciences, since March 2019. Prior to joining Abingworth, Dr. Muralidhar was a senior partner at MVM Partners LLP from November 2012 to March 2019. Prior to MVM, he was a member of Bain Capital LP’s leverage buyout team, focusing on healthcare from April 2011 to November 2012. Dr. Muralidhar currently serves on the supervisory board of Valneva SE, a French biotechnology company traded on the Vienna Stock Exchange and previously served on the board of directors of Wilson Therapeutics AB, a Swedish biopharmaceutical company traded on the Nasdaq Stockholm. Dr. Muralidhar earned a degree in clinical medicine from the University of Oxford and has a Ph.D. in translational cancer research from the MRC Cancer Cell Unit, University of Cambridge. Our Board believes that Dr. Muralidhar’s experience working with and investing in companies in the life sciences industry qualifies him to serve on the Board.
What is the salary of Bali Muralidhar?
As the Independent Director of Exicure Inc, the total compensation of Bali Muralidhar at Exicure Inc is $109,468. There are 4 executives at Exicure Inc getting paid more, with David Giljohann having the highest compensation of $785,462.
How old is Bali Muralidhar?
Bali Muralidhar is 40, he's been the Independent Director of Exicure Inc since 2019. There are 10 older and 1 younger executives at Exicure Inc. The oldest executive at Exicure Inc is David Walt, 67, who is the Independent Director.
What's Bali Muralidhar's mailing address?
Bali's mailing address filed with the SEC is C/O SPRUCE BIOSCIENCES, INC., 611 GATEWAY BOULEVARD, SUITE 740, SOUTH SAN FRANCISCO, CA, 94080.
Insiders trading at Exicure Inc
Over the last 6 years, insiders at Exicure Inc have traded over $4,850,172 worth of Exicure Inc stock and bought 7,217,940 units worth $10,705,021 . The most active insiders traders include Timothy P Walbert, Co., Ltd. Dgp und Usa, Inc. Cbi. On average, Exicure Inc executives and independent directors trade stock every 90 days with the average trade being worth of $928,360. The most recent stock trade was executed by Co., Ltd. Dgp on 29 February 2024, trading 3,400,000 units of XCUR stock currently worth $4,488,000.
What does Exicure Inc do?
exicure, formerly aurasense therapeutics, is developing a new class of immunomodulatory and gene silencing drugs against validated targets. our 3-dimensional, spherical nucleic acid (sna™) architecture unlocks the potential of nucleic acid therapeutics in multiple organs. our lead programs address diseases from inflammatory disorders to oncology. sna constructs overcome one of the most difficult obstacles to nucleic acid therapeutics: safe and effective delivery into cells and tissues. sna constructs exhibit unparalleled transfection efficiency into numerous cell and tissue types including the skin without carriers or transfection agents. moreover, snas can be used as potent immunotherapeutic agents for the treatment of cancer or infectious disease.
What does Exicure Inc's logo look like?
Complete history of Mr. Muralidhar stock trades at Exicure Inc und Spruce Biosciences
Exicure Inc executives and stock owners
Exicure Inc executives and other stock owners filed with the SEC include:
-
David Giljohann,
Chief Executive Officer, Interim Principal Financial Officer, Corporate Secretary, Director -
Matthias Schroff,
Chief Operating Officer -
Dr. Douglas E. Feltner,
Chief Medical Officer -
Chad Mirkin,
Director -
Bali Muralidhar,
Independent Director -
Bosun Hau,
Independent Director -
Jay Venkatesan,
Independent Director -
Helen Kim,
Independent Director -
Timothy Walbert,
Independent Chairman of the Board -
David Walt,
Independent Director -
Jeffrey Cleland,
Independent Director -
Karen Sharma,
Investor Relations -
Bart Anderson,
Sr. Director of R&D -
Dr. Emil M. deGoma M.D.,
VP of Clinical Devel. -
Weston Daniel,
VP of Translational Research -
Sarah Longoria,
VP of HR -
Christoph Jaeker,
VP of Corp. Devel. & Strategy -
Elias D. Papadimas,
Chief Accounting Officer -
Brian C. Bock,
Chief Financial Officer -
Elizabeth A. Garofalo,
Director -
Andy Sassine,
Director -
Llc Aurasense,
10% owner -
Douglas E. Feltner,
Chief Medical Officer -
James R Sulat,
Director -
Colby Shad Thaxton,
Director -
David S Snyder,
Chief Financial Officer -
Frontier, Llcgates William ...,
-
Brian Bock,
Chief Financial Officer -
Co., Ltd. Dgp,
-
Elias D. Papadimas,
Chief Financial Officer -
Sarah Longoria,
Chief HR & Compliance Officer -
Usa, Inc. Cbi,
-
Jiyoung Hwang,
Director -
Josh Miller,
Chief Accounting Officer